JP2017509594A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509594A5 JP2017509594A5 JP2016549123A JP2016549123A JP2017509594A5 JP 2017509594 A5 JP2017509594 A5 JP 2017509594A5 JP 2016549123 A JP2016549123 A JP 2016549123A JP 2016549123 A JP2016549123 A JP 2016549123A JP 2017509594 A5 JP2017509594 A5 JP 2017509594A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated polypeptide
- optionally
- polypeptide
- isolated
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 40
- 229920001184 polypeptide Polymers 0.000 claims 37
- 102000004196 processed proteins & peptides Human genes 0.000 claims 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 238000010494 dissociation reaction Methods 0.000 claims 4
- 230000005593 dissociations Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108010075254 C-Peptide Proteins 0.000 claims 3
- 108091005804 Peptidases Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000006043 T cell recruitment Effects 0.000 claims 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000000873 masking effect Effects 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 claims 1
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 108010091175 Matriptase Proteins 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
- 229930188854 dolastatin Natural products 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 1
- 229960005501 duocarmycin Drugs 0.000 claims 1
- 229930184221 duocarmycin Natural products 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021016630A JP7337864B2 (ja) | 2014-01-31 | 2021-02-04 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
| JP2023134791A JP2023159314A (ja) | 2014-01-31 | 2023-08-22 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934619P | 2014-01-31 | 2014-01-31 | |
| US61/934,619 | 2014-01-31 | ||
| US201461971009P | 2014-03-27 | 2014-03-27 | |
| US61/971,009 | 2014-03-27 | ||
| PCT/US2015/013776 WO2015116933A2 (en) | 2014-01-31 | 2015-01-30 | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021016630A Division JP7337864B2 (ja) | 2014-01-31 | 2021-02-04 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509594A JP2017509594A (ja) | 2017-04-06 |
| JP2017509594A5 true JP2017509594A5 (enExample) | 2018-03-08 |
| JP6835586B2 JP6835586B2 (ja) | 2021-02-24 |
Family
ID=52484571
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549123A Active JP6835586B2 (ja) | 2014-01-31 | 2015-01-30 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
| JP2021016630A Active JP7337864B2 (ja) | 2014-01-31 | 2021-02-04 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
| JP2023134791A Pending JP2023159314A (ja) | 2014-01-31 | 2023-08-22 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021016630A Active JP7337864B2 (ja) | 2014-01-31 | 2021-02-04 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
| JP2023134791A Pending JP2023159314A (ja) | 2014-01-31 | 2023-08-22 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9562073B2 (enExample) |
| EP (3) | EP4176896B1 (enExample) |
| JP (3) | JP6835586B2 (enExample) |
| KR (1) | KR102466591B1 (enExample) |
| CN (2) | CN106459153B (enExample) |
| AU (3) | AU2015210862B2 (enExample) |
| BR (1) | BR112016017649B1 (enExample) |
| DK (1) | DK3628328T3 (enExample) |
| ES (1) | ES2932777T3 (enExample) |
| IL (5) | IL302642B2 (enExample) |
| NZ (1) | NZ722401A (enExample) |
| RU (1) | RU2016135239A (enExample) |
| WO (1) | WO2015116933A2 (enExample) |
| ZA (1) | ZA202208159B (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| EP4067383A1 (en) * | 2013-07-25 | 2022-10-05 | Cytomx Therapeutics Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| CA2925106C (en) | 2013-09-25 | 2023-11-14 | Cytomx Therapeutics, Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| EP4176896B1 (en) | 2014-01-31 | 2025-10-08 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| WO2016014974A2 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| JP6841754B2 (ja) | 2015-05-13 | 2021-03-10 | 中外製薬株式会社 | 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法 |
| EA034582B1 (ru) * | 2015-08-07 | 2020-02-21 | АЭлЭкс ОНКОЛОДЖИ ИНК. | Конструкции варианта sirp-альфа и их применение |
| US10259859B2 (en) | 2015-08-07 | 2019-04-16 | ALX Oncology Inc. | Constructs having a SIRP-α domain or variant thereof |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| CN106519037B (zh) * | 2015-09-11 | 2019-07-23 | 科济生物医药（上海）有限公司 | 可活化的嵌合受体 |
| AU2016358296B2 (en) | 2015-11-19 | 2020-05-21 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| CA3013479A1 (en) | 2016-02-16 | 2017-08-24 | Carl NOVINA | Immunotherapy compositions and methods |
| BR112019008265A2 (pt) | 2016-11-28 | 2019-07-09 | Chugai Pharmaceutical Co Ltd | molécula de ligação ao ligante cuja atividade de li-gação ao ligante é ajustável |
| AU2017364817B2 (en) | 2016-11-28 | 2023-11-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding domain, and polypeptide including conveying section |
| NZ753324A (en) | 2016-12-09 | 2022-02-25 | Seagen Inc | Bivalent antibodies masked by coiled coils |
| EP3619235A1 (en) | 2017-04-11 | 2020-03-11 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| CN108690138A (zh) * | 2017-04-12 | 2018-10-23 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用 |
| US11643463B2 (en) | 2017-05-19 | 2023-05-09 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| WO2019018828A1 (en) * | 2017-07-20 | 2019-01-24 | Cytomx Therapeutics, Inc. | METHODS OF QUALITATIVE AND / OR QUANTITATIVE ANALYSIS OF ACTIVATABLE ANTIBODY PROPERTIES AND USES THEREOF |
| JP2020531430A (ja) * | 2017-08-16 | 2020-11-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗体を標的とする抗ｃｔｌａ４プロボディ療法 |
| BR112020007309A2 (pt) | 2017-10-14 | 2020-09-29 | Cytomx Therapeutics, Inc. | anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos |
| JP7330517B2 (ja) * | 2017-10-20 | 2023-08-22 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 異種タンパク質産生のための人工分泌ペプチド |
| TWI880235B (zh) | 2017-11-28 | 2025-04-11 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
| JP7482630B2 (ja) | 2017-11-28 | 2024-05-14 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| EP3769309A1 (en) | 2018-03-20 | 2021-01-27 | Cytomx Therapeutics Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
| SG11202009804RA (en) | 2018-04-11 | 2020-11-27 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
| EP3794023A1 (en) | 2018-05-14 | 2021-03-24 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| FI3794024T3 (fi) | 2018-05-14 | 2023-08-10 | Werewolf Therapeutics Inc | Aktivoitavia interleukiini-2-polypeptidejä ja niiden käyttömenetelmiä |
| JPWO2019230868A1 (ja) | 2018-05-30 | 2021-06-24 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
| JP7414736B2 (ja) | 2018-05-30 | 2024-01-16 | 中外製薬株式会社 | アグリカン結合ドメインおよび運搬部分を含むポリペプチド |
| TW202035451A (zh) | 2018-07-24 | 2020-10-01 | 美商英伊布里克斯公司 | 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法 |
| JP2022500400A (ja) * | 2018-09-11 | 2022-01-04 | ジョージア テック リサーチ コーポレイション | 免疫療法プロファイリングのための組成物および方法 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| JP7453219B2 (ja) | 2018-10-11 | 2024-03-19 | インヒブリックス， インコーポレイテッド | Ｐｄ－１単一ドメイン抗体およびその治療用組成物 |
| US20210340273A1 (en) | 2018-10-11 | 2021-11-04 | Inhlbrx, inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
| US20230124851A1 (en) | 2018-10-11 | 2023-04-20 | Inhibrx, lnc. | B7h3 single domain antibodies and therapeutic compositions thereof |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| MY205459A (en) | 2018-12-06 | 2024-10-22 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| JP7680954B2 (ja) | 2018-12-26 | 2025-05-21 | シティ・オブ・ホープ | 活性化可能なマスクされた抗ｃｔｌａ４結合タンパク質 |
| EP3902913A1 (en) | 2018-12-28 | 2021-11-03 | Catalyst Biosciences, Inc. | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| KR20220022112A (ko) | 2019-03-21 | 2022-02-24 | 이뮤노젠 아이엔씨 | 세포-결합 제제-약물 콘쥬게이트를 준비하는 방법 |
| PT3958977T (pt) | 2019-04-26 | 2023-12-15 | Immunogen Inc | Derivados de camptotecina |
| AU2020275877B2 (en) | 2019-05-14 | 2025-07-24 | Werewolf Therapeutics, Inc. | Separation moieties and methods and use thereof |
| KR20220044904A (ko) | 2019-05-31 | 2022-04-12 | 알렉소 온콜로지 인크. | 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법 |
| KR20220017430A (ko) | 2019-06-05 | 2022-02-11 | 추가이 세이야쿠 가부시키가이샤 | 항체 절단 부위 결합 분자 |
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| JP2023503258A (ja) | 2019-11-14 | 2023-01-27 | ウェアウルフ セラピューティクス， インコーポレイテッド | 活性化可能サイトカインポリペプチド及びその使用方法 |
| BR112022014667A2 (pt) | 2020-01-29 | 2022-09-20 | Inhibrx Inc | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos |
| CA3174665A1 (en) | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| KR20220167295A (ko) | 2020-04-10 | 2022-12-20 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능한 사이토카인 작제물과 관련된 조성물 및 방법 |
| WO2021217120A2 (en) * | 2020-04-24 | 2021-10-28 | Administrators Of The Tulane Educational Fund | Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor |
| KR20230005952A (ko) | 2020-05-04 | 2023-01-10 | 임뮤노라이즌 엘티디. | 전구체 삼중-특이적 항체 구조체 및 그의 이용 방법 |
| EP4196488B1 (en) | 2020-08-11 | 2025-08-06 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| US11555078B2 (en) | 2020-12-09 | 2023-01-17 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigens |
| WO2022140388A1 (en) | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
| WO2022197764A2 (en) | 2021-03-16 | 2022-09-22 | Cytomx Therapeutics, Inc. | Masked activatable cytokine constructs and related compositions and methods |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| US20240384323A1 (en) | 2021-08-30 | 2024-11-21 | Cytomx Therapeutics, Inc. | Method for determining protease activity in a biological sample |
| KR20240082350A (ko) | 2021-10-08 | 2024-06-10 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| TW202334185A (zh) | 2021-10-08 | 2023-09-01 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 可經活化之細胞介素構築體和組合方法 |
| IL312143A (en) | 2021-10-15 | 2024-06-01 | Amgen Inc | An activatable polypeptide complex |
| WO2023064955A1 (en) | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex |
| CA3234609A1 (en) | 2021-10-15 | 2023-04-20 | Leila M. BOUSTANY | Activatable polypeptide complex |
| EP4496816A1 (en) | 2022-03-23 | 2025-01-29 | CytomX Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| CN119301151A (zh) | 2022-03-25 | 2025-01-10 | 西托姆克斯治疗公司 | 可激活双锚定掩蔽分子和其使用方法 |
| TW202423953A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割部分及其使用方法 |
| AR130077A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Substratos escindibles por proteasas, y métodos de uso de los mismos |
| AR130078A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Substratos escindibles por proteasas, y métodos de uso de los mismos |
| WO2024030843A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| EP4565260A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| EP4619420A1 (en) | 2022-11-16 | 2025-09-24 | Regeneron Pharmaceuticals, Inc. | Chimeric proteins comprising membrane bound il-12 with protease cleavable linkers |
| WO2024216194A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2024216146A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
| TW202540188A (zh) | 2023-12-01 | 2025-10-16 | 比利時商艾伯霖克斯公司 | 精準活化的多肽 |
| WO2025235515A1 (en) | 2024-05-07 | 2025-11-13 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex formulations |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| EP0904386A2 (en) | 1996-05-10 | 1999-03-31 | Danisco A/S | alpha-GLUCURONIDASES OF ASPERGILLUS, PRODUCTION THEREOF AND THEIR USES |
| AUPO930697A0 (en) | 1997-09-19 | 1997-10-09 | Walter And Eliza Hall Institute Of Medical Research, The | Catalytic antibodies and a method of producing same |
| US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| ATE380865T1 (de) | 1998-05-13 | 2007-12-15 | Domantis Ltd | Phagen-display-selektionssystem für korrekt gefaltete proteine |
| CA2395885A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20110131679A2 (en) | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| WO2001091798A2 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| AU2001280464A1 (en) * | 2000-08-04 | 2002-02-18 | Eli Lilly And Company | C1q-related factor, homologous polypeptides and therapeutic uses thereof |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| AU2001293995B2 (en) | 2000-10-09 | 2005-10-13 | Cytomx Therapeutics, Inc. | Therapeutic antibodies |
| WO2002038796A2 (en) | 2000-11-08 | 2002-05-16 | Beth Israel Deaconess Medical Center, Inc. | Methods for determining protease cleavage site motifs |
| US20050208602A1 (en) | 2001-08-10 | 2005-09-22 | Rosen Craig A | 89 human secreted proteins |
| US7439319B2 (en) | 2001-09-14 | 2008-10-21 | Burnham Institute For Medical Research | Selective substrates for matrix metalloproteinases |
| WO2003038083A1 (en) * | 2001-10-29 | 2003-05-08 | Bayer Healthcare Ag | Regulation of human type i adenylate cyclase |
| EP1572908A4 (en) | 2002-02-14 | 2008-10-22 | William J Rutter | CHIMERIC MOLECULES FOR ADMINISTERING CLEAVAGE TO A TREATED HOST |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| US9079936B2 (en) | 2003-07-01 | 2015-07-14 | University Of Maryland, Baltimore | Derivatives of APF and methods of use |
| GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| DE602005027399D1 (de) * | 2004-12-20 | 2011-05-19 | Amgen Fremont Inc | Für humane matriptase spezifische bindungsproteine |
| AU2006235276A1 (en) * | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | CACNA1E in cancer diagnosis, detection and treatment |
| US7666817B2 (en) | 2005-08-31 | 2010-02-23 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| CN101340928B (zh) * | 2005-10-21 | 2011-12-21 | 催化剂生物科学公司 | 抑制补体激活的修饰的蛋白酶 |
| EP1993608A1 (en) | 2006-03-10 | 2008-11-26 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| EP2061814B1 (en) | 2006-10-27 | 2012-06-06 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| GB0819287D0 (en) | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
| US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| BRPI1006141B8 (pt) | 2009-01-12 | 2021-05-25 | Cytomx Therapeutics Llc | composições de anticorpo modificado, métodos para preparar e usar as mesmas |
| CA2753294A1 (en) * | 2009-02-23 | 2010-08-26 | Cytomx Therapeutics, Inc. | Proproteins and methods of use thereof |
| EP2427479B1 (en) | 2009-05-07 | 2018-11-21 | The Regents of The University of California | Antibodies and methods of use thereof |
| EP2473620A4 (en) | 2009-09-02 | 2013-06-05 | Univ Kansas State | MRI AND OPTICAL ASSAYS FOR PROTEASES |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| US20110214205A1 (en) | 2010-02-26 | 2011-09-01 | Monsanto Technology Llc. | Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits |
| NZ703378A (en) * | 2010-05-20 | 2016-10-28 | Allergan Inc | Degradable clostridial toxins |
| JP6400470B2 (ja) | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| US9931408B2 (en) * | 2011-05-16 | 2018-04-03 | Koninklijke Philips N.V. | Bio-orthogonal drug activation |
| US20130078201A1 (en) | 2011-09-28 | 2013-03-28 | Susan Daly | Topical sunscreen compositions |
| RU2713121C2 (ru) * | 2012-04-27 | 2020-02-03 | Сайтомкс Терапьютикс, Инк. | Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения |
| US9856314B2 (en) * | 2012-06-22 | 2018-01-02 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
| RU2015101803A (ru) * | 2012-06-22 | 2016-08-20 | Сайтомкс Терапьютикс, Инк. | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения |
| US9309510B2 (en) | 2012-08-10 | 2016-04-12 | Cytomx Therapeutics, Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| WO2014052462A2 (en) | 2012-09-25 | 2014-04-03 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| WO2014107559A1 (en) | 2013-01-03 | 2014-07-10 | Branders.Com, Inc. | Methods and apparatus for determining a score value for criteria associated with a gift |
| AU2014204015A1 (en) | 2013-01-04 | 2015-07-09 | Cytomx Therapeutics, Inc. | Compositions and methods for detecting protease activity in biological systems |
| HK1222122A1 (zh) | 2013-04-22 | 2017-06-23 | Avelas Biosciences, Inc. | 选择性药物递送组合物及使用方法 |
| EA035322B1 (ru) | 2013-05-28 | 2020-05-28 | ДиЭсБи-ЮЭсЭй ЛЛК | Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения |
| CA2925106C (en) | 2013-09-25 | 2023-11-14 | Cytomx Therapeutics, Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| EP4176896B1 (en) | 2014-01-31 | 2025-10-08 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| WO2016014974A2 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| WO2016179335A1 (en) * | 2015-05-04 | 2016-11-10 | Cytomx Therapeutics, Inc. | Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof |
| MY194184A (en) * | 2015-05-04 | 2022-11-17 | Cytomx Therapeutics Inc | Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof |
| IL292798A (en) * | 2015-05-04 | 2022-07-01 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses |
| AU2016294440B2 (en) | 2015-07-13 | 2022-10-13 | Cytomx Therapeutics, Inc | Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof |
| KR102584340B1 (ko) | 2016-11-03 | 2023-10-10 | 브리스톨-마이어스 스큅 컴퍼니 | 활성화가능한 항-ctla-4 항체 및 그의 용도 |
| CA3055574A1 (en) | 2017-03-09 | 2018-09-13 | Cytomx Therapeutics, Inc. | Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| MY205459A (en) | 2018-12-06 | 2024-10-22 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
-
2015
- 2015-01-30 EP EP22195225.2A patent/EP4176896B1/en active Active
- 2015-01-30 EP EP15705429.7A patent/EP3099319A2/en not_active Withdrawn
- 2015-01-30 ES ES19194203T patent/ES2932777T3/es active Active
- 2015-01-30 RU RU2016135239A patent/RU2016135239A/ru not_active Application Discontinuation
- 2015-01-30 IL IL302642A patent/IL302642B2/en unknown
- 2015-01-30 IL IL317045A patent/IL317045A/en unknown
- 2015-01-30 JP JP2016549123A patent/JP6835586B2/ja active Active
- 2015-01-30 IL IL294782A patent/IL294782B2/en unknown
- 2015-01-30 DK DK19194203.6T patent/DK3628328T3/da active
- 2015-01-30 WO PCT/US2015/013776 patent/WO2015116933A2/en not_active Ceased
- 2015-01-30 AU AU2015210862A patent/AU2015210862B2/en active Active
- 2015-01-30 EP EP19194203.6A patent/EP3628328B1/en active Active
- 2015-01-30 CN CN201580016781.6A patent/CN106459153B/zh active Active
- 2015-01-30 IL IL270562A patent/IL270562B/en unknown
- 2015-01-30 CN CN202111432527.8A patent/CN114106099B/zh active Active
- 2015-01-30 KR KR1020167023971A patent/KR102466591B1/ko active Active
- 2015-01-30 NZ NZ722401A patent/NZ722401A/en unknown
- 2015-01-30 BR BR112016017649-9A patent/BR112016017649B1/pt active IP Right Grant
- 2015-01-30 US US14/610,468 patent/US9562073B2/en active Active
-
2016
- 2016-07-27 IL IL246988A patent/IL246988A0/en unknown
- 2016-12-27 US US15/390,975 patent/US10138272B2/en active Active
-
2018
- 2018-10-15 US US16/160,846 patent/US11028126B2/en active Active
-
2020
- 2020-07-14 AU AU2020205249A patent/AU2020205249B2/en active Active
-
2021
- 2021-02-04 JP JP2021016630A patent/JP7337864B2/ja active Active
- 2021-04-26 US US17/240,278 patent/US11884746B2/en active Active
-
2022
- 2022-07-21 ZA ZA2022/08159A patent/ZA202208159B/en unknown
-
2023
- 2023-08-22 JP JP2023134791A patent/JP2023159314A/ja active Pending
- 2023-12-07 AU AU2023278068A patent/AU2023278068A1/en active Pending
- 2023-12-08 US US18/534,263 patent/US20240150402A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509594A5 (enExample) | ||
| JP2022065174A5 (enExample) | ||
| JP2022046569A5 (enExample) | ||
| RU2016135239A (ru) | Субстраты матриптазы и u-активатора плазминогена и другие расщепляемые остатки и способы их применения | |
| US11986535B2 (en) | Method of producing an immunoligand/payload conjugate | |
| JP2022064924A5 (enExample) | ||
| JP2018520092A5 (enExample) | ||
| Batra et al. | Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR (Fv)-PE40 and DT388-anti-TFR (Fv) | |
| JP3474574B2 (ja) | 結合特異性を有する組換ジスルフィド安定化ポリペプチドフラグメント | |
| Dimasi et al. | The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators | |
| JP2016521707A5 (enExample) | ||
| RU2015101803A (ru) | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения | |
| JP2015516813A5 (enExample) | ||
| JP2017523176A5 (enExample) | ||
| JP2018520991A5 (enExample) | ||
| JP2016525551A5 (enExample) | ||
| JP2021502810A5 (enExample) | ||
| HRP20200721T1 (hr) | Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe | |
| JP2018520091A5 (enExample) | ||
| JP2022512043A (ja) | 合理的に設計された新規なタンパク質組成物 | |
| KR20110100260A (ko) | Ｓｐａｒｃ 결합 ｓｃｆｖｓ | |
| RU2011138951A (ru) | Пропротеины и способы их применения | |
| JPH05502039A (ja) | 多価抗原結合性蛋白質 | |
| JP2012529891A5 (enExample) | ||
| JP2021512159A5 (enExample) |